 |
27 Products |  |
14 Diseases | | 27 Products |
|
13 Trials |  |
837 News |  |
| «123456789» |
- ||||| MEDI0457 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Clinical: @myESMO Safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC) present by @CharuAggarwalMD 👏🏻 #ESMO20 👆🏻 @OncoAlert @PatelOncology @gary_lyman @GlopesMd (Twitter) - Sep 18, 2020
- || INO-4800 / Inovio, The Wistar Institute
Do you have #DNA INO-4800 in your Covid19 collection? (Twitter) - Sep 14, 2020
- || INO-4500 / Inovio
Trial completion date, Trial primary completion date, Combination therapy: Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) - Sep 14, 2020
P1, N=220, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Mar 2022 --> Jun 2022 | Trial primary completion date: Mar 2022 --> Jun 2022
- ||| INO-4800 / Inovio, The Wistar Institute
Is @InovioPharma claims of their covid vaccine is true. Can any of you please share your thoughts on another nucleic acid-based #COVID19 vaccine candidate INO-4800. @elliott_blkwd (Twitter) - Sep 12, 2020
- || INO-4800 / Inovio, The Wistar Institute
DNA platform #ino4800 may hold the answer. (Twitter) - Sep 12, 2020
- | INO-4800 / Inovio, The Wistar Institute
🧬INO-4800.only safe vaccine🧬 I-N-O-V-I-O🧬 (Twitter) - Sep 8, 2020
- || INO-4800 / Inovio, The Wistar Institute
And yes, Samsung too. We see INO-4800 can open a lot of doors for Inovio. (Twitter) - Sep 8, 2020
- | INO-4800 / Inovio, The Wistar Institute
Approve Leronimab and INO-4800 (Twitter) - Sep 1, 2020
- || INO-9012 / Inovio, INO-5401 / Inovio
Dr. Reardon on the Potential Utility of INO-5401 and INO-9012 in Glioblastoma https://t.co/d59T21wSyY via @onclive (Twitter) - Aug 19, 2020
- ||| INO-4800 / Inovio, The Wistar Institute
Enrollment open: Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19 (clinicaltrials.gov) - Aug 19, 2020
P1/2, N=160, Recruiting, Sponsor: International Vaccine Institute
Trial completion date: Mar 2022 --> Jun 2022 | Trial primary completion date: Mar 2022 --> Jun 2022 Not yet recruiting --> Recruiting
- |||| INO-4800 / Inovio, The Wistar Institute
Clinical, Adverse events: Dr. Fauci, Inovio's INO-4800 shows 94% or higher effectiveness w/o any serious side effect in a Phase 1 clinical trial on humans! Yet little coverage of this in media! @realDonaldTrump @CEPIvaccines @CDCDirector @BillGates @TIME @InovioPharma @inoviolt https://t.co/bhFsves3xm (Twitter) - Aug 12, 2020
- || INO-4800 / Inovio, The Wistar Institute
Enrollment closed: Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers (clinicaltrials.gov) - Aug 11, 2020
P1, N=120, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- MEDI0457 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
[VIRTUAL] Safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC) (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1431;
P1b/2a
Funding: AstraZeneca. Clinical trial identification: NCT03162224.
- || neoantigen DNA vaccine / Washington University School of Medicine in St. Louis, AstraZeneca
Enrollment open: Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov) - Jul 16, 2020
P1, N=6, Recruiting, Sponsor: Washington University School of Medicine
Clinical trial identification: NCT03162224. Not yet recruiting --> Recruiting
- ||| bizalimogene ralaplasmid (VGX-3100) / Inovio
Enrollment open: VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions (clinicaltrials.gov) - Jul 7, 2020
P2, N=80, Recruiting, Sponsor: AIDS Malignancy Consortium
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- |||| INO-4800 / Inovio, The Wistar Institute
New P1/2 trial: Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19 (clinicaltrials.gov) - Jun 25, 2020
P1/2, N=160, Not yet recruiting, Sponsor: International Vaccine Institute
- ||| INO-3107 / Inovio
Enrollment open: INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP) (clinicaltrials.gov) - Jun 18, 2020
P1/2, N=63, Recruiting, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- || INO-4700 / Inovio, GeneOne
Clinical, P1 data, Journal: Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. (Pubmed Central) - Jun 15, 2020
P1
Immune responses were dose-independent, detected in more than 85% of participants after two vaccinations, and durable through 1 year of follow-up. The data support further development of the GLS-5300 vaccine, including additional studies to test the efficacy of GLS-5300 in a region endemic for MERS coronavirus.
- | neoantigen DNA vaccine / Washington University School of Medicine in St. Louis, AstraZeneca
Trial completion date, Trial initiation date, Trial primary completion date: Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov) - Jun 11, 2020
P1, N=6, Not yet recruiting, Sponsor: Washington University School of Medicine
The data support further development of the GLS-5300 vaccine, including additional studies to test the efficacy of GLS-5300 in a region endemic for MERS coronavirus. Trial completion date: Apr 2024 --> Aug 2024 | Initiation date: Apr 2020 --> Aug 2020 | Trial primary completion date: Jul 2023 --> Nov 2023
- || INO-4500 / Inovio
Trial completion date, Trial primary completion date, Combination therapy: Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) - Jun 11, 2020
P1, N=220, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Apr 2024 --> Aug 2024 | Initiation date: Apr 2020 --> Aug 2020 | Trial primary completion date: Jul 2023 --> Nov 2023 Trial completion date: Dec 2021 --> Mar 2022 | Trial primary completion date: Dec 2021 --> Mar 2022
- | INO-4800 / Inovio, The Wistar Institute
It easy, use @InovioPharma INO-4800. (Twitter) - Jun 9, 2020
- || INO-4800 / Inovio, The Wistar Institute
Enrollment change, Trial completion date, Trial primary completion date: Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers (clinicaltrials.gov) - Jun 4, 2020
P1, N=120, Recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Dec 2021 --> Mar 2022 | Trial primary completion date: Dec 2021 --> Mar 2022 N=40 --> 120 | Trial completion date: Apr 2021 --> Jul 2021 | Trial primary completion date: Apr 2021 --> Jul 2021
- | INO-4800 / Inovio, The Wistar Institute
Journal: Immunogenicity of a DNA vaccine candidate for COVID-19. (Pubmed Central) - May 27, 2020
Following immunization of mice and guinea pigs with INO-4800 we measure antigen-specific T cell responses, functional antibodies which neutralize the SARS-CoV-2 infection and block Spike protein binding to the ACE2 receptor, and biodistribution of SARS-CoV-2 targeting antibodies to the lungs. This preliminary dataset identifies INO-4800 as a potential COVID-19 vaccine candidate, supporting further translational study.
- ||| INO-4700 / GeneOne, Inovio
Trial completion, Trial completion date, Trial primary completion date: Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers (clinicaltrials.gov) - May 27, 2020
P1/2, N=60, Completed, Sponsor: GeneOne Life Science, Inc.
This preliminary dataset identifies INO-4800 as a potential COVID-19 vaccine candidate, supporting further translational study. Active, not recruiting --> Completed | Trial completion date: Nov 2020 --> Apr 2020 | Trial primary completion date: Sep 2020 --> May 2019
- |||| INO-3107 / Inovio
New P1/2 trial: INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP) (clinicaltrials.gov) - May 21, 2020
P1/2, N=63, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- ||| INO-4800 / Inovio, The Wistar Institute
Preclinical: $INO #COVID19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models (Twitter) - May 20, 2020
- INO-5150 / Inovio, INO-9012 / Inovio
Immunotherapy targeting PSA and PSMA in patients with biochemically recurrent prostate cancer expands antigen-specific T cell receptor repertoire in a PhI/II trial (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_4376;
Patients with immune reactivity by flow cytometry were more likely to have a higher frequency of PSA/PSMA specific TCRs that expanded >10 fold over their pre-treatment value; however patients without immune reactivity also demonstrated expansion in TCRs. These data suggest that INO-5150 induced PSA/PSMA specific T cells and that TCR sequencing is a valuable tool for assessment of immune responses induced by immunotherapy that does not bias towards a specific T cell function.
- | INO-5401 / Inovio
INO-5401 coming soon! (Twitter) - May 13, 2020
- ||| #Inovio #GBM #BARDA #CEPI #cepivaccines #INO5401 #COVID19 #INO4800 #oncology #ASCO20 (Twitter) - May 13, 2020
- | MEDI0457 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Metastases: Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer (clinicaltrials.gov) - May 5, 2020
P1b/2a, N=35, Active, not recruiting, Sponsor: MedImmune LLC
These data suggest that INO-5150 induced PSA/PSMA specific T cells and that TCR sequencing is a valuable tool for assessment of immune responses induced by immunotherapy that does not bias towards a specific T cell function. Trial completion date: Aug 2020 --> Mar 2021 | Trial primary completion date: Aug 2020 --> Mar 2021
- | INO-4800 / Inovio, The Wistar Institute
Trial completion date, Trial primary completion date: Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers (clinicaltrials.gov) - May 3, 2020
P1, N=40, Recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Aug 2020 --> Mar 2021 | Trial primary completion date: Aug 2020 --> Mar 2021 Trial completion date: Nov 2020 --> Apr 2021 | Trial primary completion date: Nov 2020 --> Apr 2021
- | rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Trial completion date, Trial primary completion date, Combination therapy, Metastases: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov) - Apr 29, 2020
P1/2, N=35, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Nov 2020 --> Apr 2021 | Trial primary completion date: Nov 2020 --> Apr 2021 Trial completion date: Sep 2020 --> Dec 2021 | Trial primary completion date: Mar 2020 --> Jul 2021
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
New P1 trial, Combination therapy, BRCA Biomarker: INO 5401 Vaccination in BRCA1/2 Mutation Carriers (clinicaltrials.gov) - Apr 28, 2020
P1b, N=28, Not yet recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- || INO-4500 / Inovio
Trial initiation date, Combination therapy: Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) - Apr 24, 2020
P1, N=220, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Sep 2020 --> Dec 2021 | Trial primary completion date: Mar 2020 --> Jul 2021 Initiation date: Mar 2020 --> Jun 2020
- INO-9012 / Inovio
[VIRTUAL] A synthetic DNA plasmid encoding HPV6 E6 and E7 proteins in patients with HPV6-associated aerodigestive lesions (Virtual Meeting: All Session Times Are U.S. EDT) - Apr 13, 2020 - Abstract #AACRI2020AACR-I_126;
P1
INO-3106, with INO-9012, given IM followed by EP with CELLECTRA® is tolerable, immunogenic, and may provide clinical benefit. A larger study is currently planned to explore the efficacy of this therapy in adults, adolescents and children with RRP.
- || INO-4800 / Inovio, The Wistar Institute
Enrollment open: Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers (clinicaltrials.gov) - Apr 8, 2020
P1, N=40, Recruiting, Sponsor: Inovio Pharmaceuticals
A larger study is currently planned to explore the efficacy of this therapy in adults, adolescents and children with RRP. Not yet recruiting --> Recruiting
- || INO-4800 / Inovio, The Wistar Institute
New P1 trial: Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers (clinicaltrials.gov) - Apr 6, 2020
P1, N=40, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- || bizalimogene ralaplasmid (VGX-3100) / Inovio
Enrollment closed: VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions (clinicaltrials.gov) - Apr 1, 2020
P2, N=80, Active, not recruiting, Sponsor: AIDS Malignancy Consortium
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || GNOS-PV02 / Geneos Therap
Enrollment open, Combination therapy, Metastases: GT-30: GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC (clinicaltrials.gov) - Mar 10, 2020
P1/2, N=12, Recruiting, Sponsor: Geneos Therapeutics
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | MEDI0457 / AstraZeneca, MEDI-547 / AstraZeneca
Journal: Immunotherapy targeting HPV 16/18 generates potent immune responses in HPV-Associated Head and Neck Cancer. (Pubmed Central) - Feb 29, 2020
These data demonstrate that MEDI0457 can generate durable HPV16/18 antigen-specific peripheral and tumor immune responses. This approach may be used as a complementary strategy to PD-1/PD-L1 inhibition in HPV-associated HNSCCa to improve therapeutic outcomes.
- Libtayo (cemiplimab) / Sanofi, Regeneron, INO-9012 / Inovio, INO-5401 / Inovio
[VIRTUAL] INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results. (Poster Board 5) - Feb 27, 2020 - Abstract #ASCO2020ASCO_166;
P1/2
OS18 data will be presented later this year. Research Funding: Inovio
- || INO-A002 / Inovio
Enrollment closed: A Study of INO-A002 in Healthy Dengue Virus-naive Adults (clinicaltrials.gov) - Feb 26, 2020
P1, N=24, Active, not recruiting, Sponsor: University of Pennsylvania
Research Funding: Inovio Recruiting --> Active, not recruiting
- || INO-4201 / Inovio
Clinical, Journal: Intradermal SynCon® Ebola GP DNA Vaccine is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers. (Pubmed Central) - Feb 24, 2020
P1
Recruiting --> Active, not recruiting Intradermal delivery of INO-4201 was well-tolerated and resulted in 100% seroreactivity after two doses and elicited interferon-γ T cell responses in over 70% of subjects, providing a new approach for EBOV prevention in diverse populations.
- | neoantigen DNA vaccine / Washington University School of Medicine in St. Louis, AstraZeneca
Trial completion date, Trial initiation date, Trial primary completion date: Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov) - Feb 17, 2020
P1, N=6, Not yet recruiting, Sponsor: Washington University School of Medicine
Intradermal delivery of INO-4201 was well-tolerated and resulted in 100% seroreactivity after two doses and elicited interferon-γ T cell responses in over 70% of subjects, providing a new approach for EBOV prevention in diverse populations. Trial completion date: Dec 2023 --> Mar 2024 | Initiation date: Dec 2019 --> Mar 2020 | Trial primary completion date: Mar 2023 --> Jun 2023
- | INO-3107 / Inovio, INO-9012 / Inovio
Journal: Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis. (Pubmed Central) - Feb 6, 2020
INO-3106 with and without INO-9012 was well tolerated, immunogenic and demonstrated preliminary efficacy in patients with HPV6-associated RRP aerodigestive lesions. Further clinical study is indicated.
- || INO-8000 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Enrollment closed: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Feb 5, 2020
P1, N=32, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Further clinical study is indicated. Recruiting --> Active, not recruiting
- | GNOS-PV02 / Geneos Therap
New P1/2 trial, Combination therapy, Metastases: GT-30: GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC (clinicaltrials.gov) - Jan 30, 2020
P1/2, N=12, Not yet recruiting, Sponsor: Geneos Therapeutics
- | Tecfidera (dimethyl fumarate) / Biogen
Journal: Effects of GIT-27NO, a NO-donating compound, on hepatic ischemia/reperfusion injury. (Pubmed Central) - Jan 24, 2020
GIT-27NO is a NO-derivative of the toll-like receptor 4 antagonist VGX-1027 that has been shown to possess both antineoplastic and immunomodulatory properties in vitro and in vivo...These effects were almost similar to that of the positive control drug dimethyl fumarate. These data suggest that the beneficial effect of GIT-27NO in the hepatic IRI can be secondary to anti-oxidative effects and hepatocyte necrosis reduction probably mediated by NO release.
- || INO-4500 / Inovio
Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy: Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) - Dec 29, 2019
P1, N=225, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
These data suggest that the beneficial effect of GIT-27NO in the hepatic IRI can be secondary to anti-oxidative effects and hepatocyte necrosis reduction probably mediated by NO release. Trial completion date: Jul 2021 --> Oct 2021 | Initiation date: Dec 2019 --> Mar 2020 | Trial primary completion date: Jul 2021 --> Oct 2021
- ||| MEDI0457 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, PD(L)-1 Biomarker: Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients (clinicaltrials.gov) - Dec 3, 2019
P2, N=66, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Jul 2021 --> Oct 2021 | Initiation date: Dec 2019 --> Mar 2020 | Trial primary completion date: Jul 2021 --> Oct 2021 Not yet recruiting --> Recruiting